Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases.

Li, Zhaoyang; Follman, Kristin; Freshwater, Ed; Engler, Frank; Yel, Leman

Li, Zhaoyang; Follman, Kristin; Freshwater, Ed; Engler, Frank; Yel, Leman.

Li Z; Takeda Development Center Americas, Inc., 650 Kendall Street, Cambridge, MA, 02142, USA. zhaoyang.li@takeda.com.
Follman K; Certara Strategic Consulting, Certara USA, Princeton, NJ, USA.
Freshwater E; Certara Strategic Consulting, Certara USA, Princeton, NJ, USA.
Engler F; Certara Strategic Consulting, Certara USA, Princeton, NJ, USA.
Yel L; Takeda Development Center Americas, Inc., 650 Kendall Street, Cambridge, MA, 02142, USA.

J Clin Immunol ; 43(8): 2127-2135, 2023 11.

Article en En | MEDLINE | ID: mdl-37773562

Asunto(s)

Inmunoglobulina G; Enfermedades de Inmunodeficiencia Primaria; Adulto; Humanos; Niño; Hialuronoglucosaminidasa; Inmunoglobulinas Intravenosas/uso terapéutico; Estado de Salud; Enfermedades de Inmunodeficiencia Primaria/tratamiento farmacológico

Palabras clave

intravenous immunoglobulin (IVIG); obesity; pediatric patients; population pharmacokinetic modeling and simulations; primary immunodeficiency diseases; subcutaneous immunoglobulin (SCIG)

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoglobulina G / Enfermedades de Inmunodeficiencia Primaria Tipo de estudio: Prognostic_studies Límite: Adult / Child / Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google